Literature DB >> 1675950

The association of hepatic apoprotein and lipid metabolism in hamsters and rats.

G L Liu1, L M Fan, R N Redinger.   

Abstract

1. The hamster liver but not that of the rat, secretes VLDL containing only apoprotein B100. Apoprotein B48 was identified in mesenteric lymph of hamsters and therefore plasma apoprotein B48 is of intestinal origin. 2. Male hamster livers secrete less free cholesterol but similar cholesterol ester than male rats resulting in a higher CE/FC ratio in hamsters. 3. Hepatic VLDL from male hamsters contain more apo B and E while that from females contains more TG and apo A-II/C. 4. Hamsters fed high-C diets secrete more hepatic VLDL-apoprotein B, -free and -cholesterol ester, and biliary cholesterol.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1675950     DOI: 10.1016/0300-9629(91)90263-c

Source DB:  PubMed          Journal:  Comp Biochem Physiol A Comp Physiol        ISSN: 0300-9629


  11 in total

1.  Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model.

Authors:  François Briand; Morgan Tréguier; Agnès André; Didier Grillot; Marc Issandou; Khadija Ouguerram; Thierry Sulpice
Journal:  J Lipid Res       Date:  2009-10-27       Impact factor: 5.922

2.  High-fructose diet downregulates long-chain acyl-CoA synthetase 3 expression in liver of hamsters via impairing LXR/RXR signaling pathway.

Authors:  Bin Dong; Chin Fung Kelvin Kan; Amar B Singh; Jingwen Liu
Journal:  J Lipid Res       Date:  2013-02-20       Impact factor: 5.922

3.  High-Fructose Consumption Impairs the Redox System and Protein Quality Control in the Brain of Syrian Hamsters: Therapeutic Effects of Melatonin.

Authors:  Juan Carlos Bermejo-Millo; Marcela Rodrigues Moreira Guimarães; Beatriz de Luxán-Delgado; Yaiza Potes; Zulema Pérez-Martínez; Andrea Díaz-Luis; Beatriz Caballero; Juan José Solano; Ignacio Vega-Naredo; Ana Coto-Montes
Journal:  Mol Neurobiol       Date:  2018-02-28       Impact factor: 5.590

4.  Genetically Engineered Hamster Models of Dyslipidemia and Atherosclerosis.

Authors:  Xunde Xian; Yuhui Wang; George Liu
Journal:  Methods Mol Biol       Date:  2022

5.  Background diet and fat type alters plasma lipoprotein response but not aortic cholesterol accumulation in F1B Golden Syrian hamsters.

Authors:  Alice Dillard; Nirupa R Matthan; Nicole L Spartano; Ann E Butkowski; Alice H Lichtenstein
Journal:  Lipids       Date:  2013-10-06       Impact factor: 1.880

6.  Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster.

Authors:  Rai Ajit K Srivastava; Shirley He
Journal:  Mol Cell Biochem       Date:  2010-08-27       Impact factor: 3.396

7.  Delineation of molecular pathways that regulate hepatic PCSK9 and LDL receptor expression during fasting in normolipidemic hamsters.

Authors:  Minhao Wu; Bin Dong; Aiqin Cao; Hai Li; Jingwen Liu
Journal:  Atherosclerosis       Date:  2012-08-24       Impact factor: 5.162

8.  Use of hamster as a model to study diet-induced atherosclerosis.

Authors:  Alice Dillard; Nirupa R Matthan; Alice H Lichtenstein
Journal:  Nutr Metab (Lond)       Date:  2010-12-10       Impact factor: 4.169

9.  Insulin treatment improves liver histopathology and decreases expression of inflammatory and fibrogenic genes in a hyperglycemic, dyslipidemic hamster model of NAFLD.

Authors:  Victoria Svop Jensen; Christian Fledelius; Christina Zachodnik; Jesper Damgaard; Helle Nygaard; Kristina Steinicke Tornqvist; Rikke Kaae Kirk; Birgitte Martine Viuff; Erik Max Wulff; Jens Lykkesfeldt; Henning Hvid
Journal:  J Transl Med       Date:  2021-02-17       Impact factor: 5.531

10.  A Hamster Model of Diet-Induced Obesity for Preclinical Evaluation of Anti-Obesity, Anti-Diabetic and Lipid Modulating Agents.

Authors:  Louise S Dalbøge; Philip J Pedersen; Gitte Hansen; Katrine Fabricius; Henrik B Hansen; Jacob Jelsing; Niels Vrang
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.